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S U M M A R Y
Background: Neutrophil CD64 expression is widely reported as an efﬁcacious biomarker to differentiate
infected patients from other non-infected patients. This meta-analysis was conducted to comprehen-
sively and quantitatively summarize the accuracy of neutrophil CD64 in the early diagnosis of bacterial
infection.
Methods: A systematic review of related studies was conducted, and the sensitivity, speciﬁcity, and other
data about the accuracy of CD64 expression on neutrophils were pooled using random effects models
with 95% conﬁdence intervals (CI) as the effect measurements. Summary receiver operating
characteristic (SROC) curves and the Q* value were also calculated in the meta-analysis. Heterogeneity
was tested, as well as the publication bias. Potential sources of heterogeneity were explored by assessing
whether or not certain covariates signiﬁcantly inﬂuenced the summary diagnostic odds ratio (SDOR).
Results: A total of 26 studies including 3944 patients met the inclusion criteria for the ﬁnal analysis. The
summary estimate was 0.76 (95% CI 0.74–0.78) for sensitivity and 0.85 (95% CI 0.83–0.86) for speciﬁcity.
The positive likelihood ratio (PLR), negative likelihood ratio (NLR), SDOR, and area under the SROC of
neutrophil CD64 expression with Q* value were 6.67 (95% CI 4.67–9.53), 0.24 (95% CI 0.18–0.31), 34.29
(95% CI 19.59–60.01), and 0.92 (Q* = 0.85), respectively. The pooled data from the included studies had
high heterogeneity and the Egger test suggested a publication bias.
Conclusions: On the basis of our meta-analysis, neutrophil CD64 expression could be a promising and
meaningful biomarker for diagnosing bacterial infection. Nevertheless, more large prospective studies
should be carried out before the neutrophil CD64 test is used widely in the clinical setting because of the
various cut-off values.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Bacterial infections are an important cause of hospital
morbidity and mortality worldwide.1 Early diagnosis of a bacterial
infection is necessary because it can evolve very rapidly and
treatment depends on antibiotic administration. Clinicians are in
need of good diagnostic and prognostic biomarkers to identify
infected patients who would beneﬁt from prompt antibiotic
therapy as early as possible. Therefore, many potential infection
biomarkers that could facilitate early diagnosis and evaluate
therapeutic effect have been investigated extensively.
Traditionally, the white blood cell (WBC) count, erythrocyte
sedimentation rate (ESR), and C-reactive protein (CRP) are utilized as* Corresponding author. Tel.: +86 0771 5356052; fax: +86 0771 865353342.
E-mail address: qinxue919@yahoo.cn (X. Qin).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.07.017common screening laboratory tests, but these have poor sensitivity
and speciﬁcity.2 Despite a positive microbiological culture widely
being considered the diagnostic gold standard of infection, this is
time-consuming and sometimes leads to false-negative outcomes
when the patient has previously received antibiotics.3 More
recently, new soluble biomarkers of infection in the serum or
plasma, such as interleukin (IL)-6, tumor necrosis factor alpha (TNF-
a), high-mobility group box-1 protein (HMGB-1), lipopolysaccha-
ride-binding protein (LBP), and procalcitonin (PCT) have been
reported.2,4–6 Of these new markers, PCT in particular has appeared
to be a promising marker for the detection of infection and sepsis.
However, recent reports and meta-analyses have demonstrated
inconsistent results and some limitations of PCT.7–11
CD64 (FcgRI), one of the Fc receptors for IgG, constitutively
presents on macrophages, monocytes, and eosinophils, and only to
a small extent on resting neutrophils. However, neutrophil CD64
expression rapidly increases in the presence of microbial wallses. Published by Elsevier Ltd. All rights reserved.
Studies excluded with reasons: 
Used healthy people as controls  (n = 6)  
Less than 10 specimens (n = 1)  
Studies included in this meta-analysis, 
n = 26 
Potentially eligible studies for full-text  
assessment, n = 33 
Publications retrieved for a more detailed 
evaluation, n = 127   
Did not report on diagnostic accuracy 
of CD64 (n = 42) 
Data for calculating sensitivity and 
specificity unavailable (n = 52) 
Studies excluded according to the first 
screening of titles and abstracts, 
n = 1512 
Potential relevant studies reviewed, 
n = 1639 
Last literature search date March 1, 2012 
PubMed (n = 659), EMBASE  (n = 980)  
Figure 1. Flow chart of the study selection.
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tory cytokines, such as interferon gamma (IFN-g) and granulocyte
colony-stimulating factor (G-CSF).2,12–14 And when these stimula-
tion factors are absent, it will substantially decrease within 48 h
and be back to normal baseline levels after 7 days.12 Quite recently,
an increasing number of studies on neutrophil CD64 expression
have been reported, showing it to be a potentially useful early
biomarker for the detection of infection and sepsis, with high
sensitivity and speciﬁcity. These results suggest that neutrophil
CD64 expression can be used as an indicator for differentiating
infected from non-infected patients at a very early stage. Moreover,
the analysis of neutrophil CD64 is relatively simple and fast, and
requires only a small volume of blood.
A previous meta-analysis15 including 13 studies16–28 was done
in 2010 to evaluate the diagnostic precision of neutrophil CD64
expression, which showed a pooled sensitivity of 0.79 (95%
conﬁdence interval (CI) 0.70–0.86) and pooled speciﬁcity of 0.91
(95% CI 0.85–0.95). However, during the last 2 years, many more
related studies have been published. As the previous meta-analysis
included a limited number of studies, and the performance of CD64
in the new studies was not consistent, we conducted this meta-
analysis to investigate the accuracy of CD64 expression on the
surface of neutrophils in the early diagnosis of bacterial infection
from all the relevant studies, including all the newly published
studies.
2. Methods
2.1. Identiﬁcation of studies
We performed a comprehensive systematic electronic search of
the EMBASE and PubMed databases for original articles published
before March 1, 2012. All searches were limited to human subjects
without language, study design, or publication status restrictions.
The search terms used were ‘‘CD64’’, ‘‘Fc gamma receptor’’,
‘‘sensitivity and speciﬁcity’’, ‘‘diagnosis’’, and ‘‘accuracy’’. Refer-
ence lists of all retrieved primary articles were reviewed manually
for any additional relevant studies.
2.2. Selection criteria
The following criteria were applied to identify studies for
inclusion in the meta-analysis: (1) studies that were observational;
(2) studies that assessed the diagnostic accuracy of CD64
expression on neutrophils for bacterial infection; (3) studies
providing both the sensitivity and speciﬁcity of CD64 expression
on neutrophils or sufﬁcient information to reconstruct the 2  2
contingency tables; (4) bacterial infection deﬁned as follows: (a)
proven infection, when a pathogen was proved by microbiological
culture; (b) clinical bacterial infection, diagnosed by obvious
symptoms of infection; or radiological ﬁndings or other imaging
diagnostics; or clinical and biochemical ﬁndings; or obvious effects
observed clinically after antibacterial therapy, etc.; (5) studies
including more than 10 cases.
Two investigators reviewed all the studies independently on
the basis of the titles and abstracts, and then the full texts of
potentially eligible trials were evaluated for further assessment.
Any letters, case reports, reviews, and conference abstracts were
excluded because of limited data. Publications identiﬁed as
duplicate reports were eliminated so that each report was unique.
Those studies that lacked the necessary data to perform 2  2
contingency tables were excluded. Studies with data on healthy
individuals used as controls were also excluded, because they are
not representative of the population to which the test would be
applied in clinical practice. Disagreements on study inclusion orexclusion were resolved through discussion with the third
investigator.
2.3. Data extraction
All of the included articles were assessed independently by two
reviewers. The data were extracted from each study including the
following individual details: ﬁrst author, publication year, region,
study population (including the numbers of cases and controls),
the type of infective disease, the means of diagnosing bacterial
infection, whether the samples were collected before antibiotic
therapy, analytical method, cut-off value, sensitivity, speciﬁcity,
positive predictive value (PPV), and negative predictive value
(NPV). If there was any disagreement between the two reviewers,
it was settled by consensus.
2.4. Study quality assessment
The methodological quality of each included study was
assessed with the diagnostic accuracy tool QUADAS (quality
assessment for studies of diagnostic accuracy),29 which is
recommended by the Cochrane Collaboration for the quality
assessment of diagnostic studies. The QUADAS tool is structured as
a list of 14 items that should each be answered ‘yes’, ‘no’, or
‘unclear’.
2.5. Statistical analysis
The statistical analysis was performed using STATA (version
9.2) and MetaDiSc (version 1.4) software.
We used the bivariate model for diagnostic meta-analysis to
perform the pooled sensitivity and speciﬁcity, positive likelihood
ratio (PLR), negative likelihood ratio (NLR), and the summary
diagnostic odds ratio (SDOR). All the pooled estimates with the
corresponding 95% CI were initially calculated using a ﬁxed-effects
model. If there was signiﬁcant heterogeneity, we switched to a
random-effects model.30 We constructed summary receiver
operator characteristic (SROC) curves based on the sensitivity
and speciﬁcity of each study to illustrate the diagnostic accuracy.
Smoothed SROC curves were then achieved by using a regression
model proposed by Moses et al.31 The SROC curve was intended to
Table 1
Baseline characteristics of the studies included in the meta-analysis
Study (year) Region Study population
(non-infected vs. infected)
Means of diagnosis of
bacterial infection
Samples collected before
antibiotic therapy
Analytical
method
Detecting instrument
Mokuda et al. (2012)53 Asia Adult patients with RA in hospital ward (25
vs. 15)
Proven infection: identiﬁed pathogen was
proven by microbiological culture or PCR
Yes FCM BD FACSCalibur
Gros et al. (2012)52 Europe Adult patients with two ormore SIRS criteria
suspected of sepsis in ICU (145 vs. 148)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
No (29 patients at risk had been treated
with antibiotics)
Leuko64 kit Coulter Epic XL-MCL
Lam et al. (2011)51 Asia Infants with clinical suspicion of neonatal
sepsis in NICU (174 vs. 136)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, b, c, d, e
Yes FCM BD FACSCalibur
Hsu et al. (2011)50 Asia Adults with two or more SIRS criteria
suspected of sepsis in RICU (11 vs. 55)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, b, c, d
Unclear FCM BD FACSCalibur
Genel et al. (2011)49 Asia Neonates suspected of neonatal infection in
NICU (35 vs. 49)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, b, c
Unclear FCM Coulter Epic XL-MCL
Ga´mez-Dı´az
et al. (2011)48
South
America
Adults with fever suspected of sepsis in ED
(206 vs. 404)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, b, c, d
Unclear Leuko64 kit Coulter Epic XL-MCL
Cid et al. (2011)47 Europe Adults with fever suspected of infection in
ED (17 vs. 115)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, b, c
Yes Leuko64 kit NR
Tang et al. (2010)46 Asia Adults with measles suspected of infection
in hospital ward (42 vs. 64)
Proven infection: identiﬁed pathogen was
proven by microbiological culture or PCR
Clinical infection:a a, b, c
Unclear FCM Coulter Epic XL-MCL
Nishino et al. (2010)45 Asia Adult patients with RA in hospital ward (36
vs. 25)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, c, d
No (48 patients had been treated with
antibiotics)
FCM BD FACSCalibur
Hussein et al. (2010)44 Africa Adults with RA/SLE suspected of infection in
hospital ward (18 vs. 18)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Yes FCM BD FACSCalibur
Doi et al. (2010)43 Asia Adults suspected of local musculoskeletal
infection in hospital ward (68 vs. 31)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, c, d
Unclear FCM BD FACSCalibur
Dilli et al. (2010)42 Asia Neonates suspected of neonatal sepsis in
NICU (42 vs. 35)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, c, d
No (11 patients at risk had been treated
with antibiotics)
Leuko64 kit BD FACSCalibur
Icardi et al. (2009)41 North
America
Adults with fever suspected of infection in
hospital ward (53 vs. 56)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, b, c, d
Yes Leuko64 kit BD FACSCalibur
Groselj-Grenc
et al. (2009)26
Europe Neonates with SIRS suspected of neonatal
sepsis in NICU (29 vs. 17)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, b, c, d
Yes Leuko64 kit BD FACSCalibur
Groselj-Grenc
et al. (2009)26
Europe Children with SIRS suspected of sepsis in
NICU (12 vs. 24)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, b, c, d
Yes Leuko64 kit BD FACSCalibur
Tanaka et al. (2009)27 Asia Adults suspected of local musculoskeletal
infection in hospital ward (95 vs. 46)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
No (76 patients had been treated with
antibiotics)
FCM BD FACSCalibur
Tillinger et al. (2009)28 North
America
Adults with active inﬂammatory bowel
disease suspected of bacterial enterocolitis
(76 vs. 22)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Unclear FCM BD FACSCalibur
Groselj-Grenc
et al. (2008)25
Europe Children and neonates with SIRS suspected
sepsis in NICU (27 vs. 29)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Clinical infection:a a, b, c, d
Yes Leuko64 kit BD FACSCalibur
Bhandari et al. (2008)23 North America Neonates suspected of neonatal sepsis in
NICU (165 vs. 128)
Proven infection: identiﬁed pathogen was
proven microbiological culture
Clinical infection:a a, b, c, d
Unclear Leuko64 kit BD FACSCalibur
Cardelli et al. (2008)24 Europe Adults with clinical suspicion of sepsis in ICU
(145 vs. 148)
Proven infection: identiﬁed pathogen was
proven by microbiological culture
Yes FCM BD FACSCalibur
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positive rates (1  speciﬁcity) across studies and display the trade-
off between sensitivity and speciﬁcity. The area under the curve
(AUC) value with Q* value was also calculated to present an overall
summary of test performance to differentiate between a diseased
and a non-diseased participant.30,32 AUC, which ranges from 0 to 1,
measures test precision from the SROC curve. A perfect test usually
has an AUC close to 1, while a poor test has an AUC close to 0.5, so
the closer AUC is to 1, the better the diagnostic accuracy. The Q*
value is the point where sensitivity and speciﬁcity are equal on the
SROC curve, which is closest to the ideal top-left corner of the SROC
space.32 We evaluated the presence of a threshold effect on the
diagnostic accuracy of CD64 expression with the Spearman
correlation coefﬁcient between the logits of sensitivity and
speciﬁcity.
The Cochran Q test and the I2 statistic were used to evaluate the
statistical heterogeneity among the studies.33 Statistically signiﬁ-
cant heterogeneity was considered when the p-value was less than
0.05 and the I2 value was more than 50%. If any heterogeneity
existed, we would try to determine the causes, and then a meta-
regression analysis and subgroup analysis were performed in order
to explain the observed heterogeneity within the included studies.
The ﬂowing potential factors were assessed both in the meta-
regression and subgroup analysis: the means of diagnosing
bacterial infection, whether or not the samples were collected
directly before antibiotic therapy, the quality of the studies, region,
study population, the type of infective disease, analytical method,
and detecting instrument. The presence of publication bias was
tested using the Egger test.34
3. Results
The systematic literature search generated a total of 1639
references based on the search strategy in PubMed and EMBASE
(659 in PubMed and 980 in EMBASE). We excluded 1512 studies
after screening the titles and abstracts, because they were not
considered relevant to our study question, and most were
eliminated because of duplication in the PubMed and EMBASE
databases. One hundred and twenty-seven articles were subject to
deeper evaluation. Forty-two references were excluded for not
reporting the diagnostic accuracy of CD64 and another 52 studies
were excluded because of insufﬁcient data for constructing the
2  2 contingency tables. Subsequently, 33 potentially eligible
studies were retrieved for full-text assessment. After reading the
full texts, seven studies were also discarded: six articles used
healthy individuals as controls4,35–39 and another included less
than 10 specimens.40 Ultimately we included a total of 26 studies
with 3944 patients in this meta-analysis.16–28,41–53 A ﬂow chart
showing the study selection is given in Figure 1.
3.1. Characteristics of the included studies and quality of the studies
The baseline characteristics of the diagnostic reports are shown
in Table 1. One report26 investigated data on the diagnostic
accuracy of neutrophil CD64 expression in two population groups,
so we treated this as two studies. The included trials were
published from 2002 to 2012. The majority of the trials were
performed in Asia and Europe; ﬁve were done in North
America,16,17,23,28,41 one in Africa,44 and one in South America.48
Furthermore, the study population of the diagnostic studies
included neonates and infants, along with adults, and most of
them were considered as sepsis. Approximately half of the subjects
were in intensive care units and the populations of another two
studies were in the emergency department. As there has
previously been no accepted gold standard for the diagnosis of
sepsis and bacterial infection, the means of diagnosis of bacterial
Table 2
Summary data from the 27 studies of CD64 expression in the diagnosis of bacterial infection
Study Cut-off Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) TP FP FN TN QUADAS
Mokuda et al.53 1800 mol/cell 93 92 87.5 95.8 14 2 1 23 10
Gros et al.52 2.2 63 89 85.3 70.1 91 16 54 132 11
Lam et al.51 6010 mol/cell 79 79 74 83 107 37 29 137 11
Hsu et al.50 4300 mol/cell 89.1 95.9 98.0 62.5 49 1 6 10 11
Genel et al.49 3.05 MFI/cell 81 77 83 75 40 8 9 27 10
Ga´mez-Dı´az et al.48 1.7 65.8 64.6 78.5 49.1 266 73 138 133 10
Cid et al.47 1.5 87 41 91 32 100 10 15 7 12
Tang et al.46 8.5 MFI/cell 78.1 76.2 83.3 69.6 50 10 14 32 9
Nishino et al.45 2000 mol/cell 76.0 94.4 90.5 85.0 19 2 6 34 11
Hussein et al.44 43.5 MFI/cell 94.4 88.9 89.5 94.1 17 2 1 16 10
Doi et al.43 2000 mol/cell 61.3 98.5 94.7 83.8 19 1 12 67 11
Dilli et al.42 4.39 88.6 85.1 73.8 94.0 31 6 4 36 12
Icardi et al.41 1.19 94.6 88.7 89.8 94.0 53 6 3 47 10
Groselj-Grenc et al.26 1.86 77 79 53 92 13 6 4 23 10
Groselj-Grenc et al.26 2.38 71 100 100 96 17 0 7 12 10
Tanaka et al.27 2000 mol/cell 60.9 97.9 93.3 83.8 28 2 18 93 11
Tillinger et al.28 10 000 mol/cell 96 97 91 97 21 2 1 74 12
Groselj-Grenc et al.25 2.45 65.5 88.9 86.4 70.6 19 3 10 24 12
Bhandari et al.23 2.3 70 62 59 73 89 63 39 102 11
Cardelli et al.24 2398 mol/cell 96 95 91 98 50 3 2 57 11
Ng et al.22 6136 mol/cell 78 90 78 90 72 20 21 175 12
Livaditi et al.20 2566 mol/cell 94.6 100 100 83.3 35 0 2 10 11
Matsui et al.21 2000 mol/cell 92.7 96.5 87.9 97.9 51 7 4 195 10
Ng et al.19 6136 mol/cell 79 89 78 89 91 25 24 198 12
Layseca-Espinosa et al.17 NR 25.8 96.8 88.9 41 8 1 23 16 9
Ng et al.18 4000 mol/cell 95 88 80 97 30 7 2 51 11
Allen et al.16 2000 mol/cell 85 91 85 91 23 4 4 40 12
FN, false negative; FP, false positive; mol, molecules; MFI, mean ﬂuorescence intensity; NPV, negative predictive value; NR, not reported; PPV, positive predictive value;
QUADAS, quality assessment for studies of diagnostic accuracy; TN, true negative; TP, true positive.
S. Li et al. / International Journal of Infectious Diseases 17 (2013) e12–e23e16infection was used in the included studies as the reference
standard to obtain the data on diagnostic accuracy. The criteria of
bacterial infection included proven infection and clinical infection;
11 studies applied proven infection and 16 studies used proven
infection or clinical infection as the clinical criteria. Whether
samples were collected before antibiotic therapy is also shown in
Table 1 for each included study. We found that in ﬁve of the
studies, those patients at risk had been treated with antibiotic
therapy before sample collection.17,27,42,45,52 All studies used ﬂow
cytometry (FCM) or Leuko64 kit performed on the Coulter Epic XL-
MCL or BD FACSCalibur to detected CD64 expression on
neutrophils. Only one study47 did not report the detecting
instrument.Figure 2. Summary of the methodological quality assessment of the included
studies according to all 14 QUADAS tool criteria. The proportions of the 26 studies
that met the criteria (yes), did not meet the criteria (no), and did not provide
adequate relevant data (unclear) are shown.Summary data on the diagnostic performance of CD64
expression in the diagnosis of bacterial infection from the 27
studies (including the study with two different populations) are
presented in Table 2. All the trials were appraised according to
QUADAS, and this is also presented in Table 2. Figure 2 shows the
summary of the methodological quality assessment of the included
studies according to all 14 QUADAS tool criteria.
3.2. Diagnostic accuracy analyses
Figure 3 shows the forest plot of sensitivity and speciﬁcity of the
27 studies using the neutrophil CD64 test in the diagnosis of
bacterial infection. The overall pooled sensitivity and speciﬁcity of
all studies were 0.76 (95% CI 0.74–0.78) and 0.85 (95% CI 0.83–
0.86), respectively. The overall pooled PLR and NLR were 6.67 (95%
CI 4.67–9.53) and 0.24 (95% CI 0.18–0.31), respectively. The SDOR
was 34.29 (95% CI 19.59–60.01) (Figure 4). All the summary
measures indicated a signiﬁcant heterogeneity between studies.
Simultaneously, we performed a diagnostic accuracy analysis for
only those patients with a proven bacterial infection. We found
that it had better outcomes in all summary measures. As shown in
Figure 5, the sensitivity, speciﬁcity, PLR, NLR, and SDOR of
neutrophil CD64 in proven bacterial infection patients were 0.78
(0.75–0.82), 0.91 (0.89–0.93), 8.79 (6.60–11.69), 0.17 (0.11–0.27),
and 65.62 (33.01–130.42), respectively.
3.3. Summary receiver-operating characteristics
As shown in Figure 6, the SROC curve for CD64 expression
showing true-positive rates against false-positive rates from
individual reports displays the trade-off between sensitivity and
speciﬁcity. Each data point in the SROC plot represents a separate
report. The SROC curve yielded an optimal joint sensitivity and
speciﬁcity. When all 27 studies were included to construct the
SROC curve (Figure 6A), the AUC for the detection of bacterial
infection was 0.92 and the Q* value was 0.85. However, if only the
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Figure 3. Forest plots of the sensitivity (A) and speciﬁcity (B) of neutrophil CD64 of all included studies for the diagnosis of bacterial infection. The solid circles represent each
individual study and the diamond represents the pooled diagnostic odds ratio. The size of the circle is proportional to the size of the included study. Error bars are 95%
conﬁdence intervals.
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Figure 4. Summary diagnostic odds ratio (SDOR) of neutrophil CD64 of all included studies for the diagnosis of bacterial infection. The solid circles represent each individual
study, and the diamond represents pooled diagnostic odds ratio. The size of each circle is proportional to the size of the included study. Error bars are 95% conﬁdence intervals.
S. Li et al. / International Journal of Infectious Diseases 17 (2013) e12–e23e18proven infection studies were evaluated, as shown in Figure 6B, the
AUC was 0.96 and the Q* value was 0.91, indicating a higher level of
diagnostic accuracy.
3.4. Investigation of heterogeneity
In diagnostic studies, one of the most important sources of the
presence of heterogeneity is the threshold effect. So we performed
a threshold analysis to explore the threshold effect, which was
evaluated with the Spearman correlation coefﬁcient, using Moses’
model weighted by inverse variance. We found there was no
statistically signiﬁcant difference (Spearman correlation
coefﬁcient = 0.112, p-value = 0.609).
The Cochran Q test and the I2 statistic were used to evaluate the
presence of statistical heterogeneity across the studies. Statistical
heterogeneity and inconsistency were found for the pooled
sensitivity (Chi-square = 175.17, I2 = 85.2%, p < 0.001), speciﬁcity
(Chi-square = 238.05, I2 = 89.1%, p < 0.001), PLR (Chi-
square = 237.27, I2 = 89.0%, p < 0.001), NLR (Chi-square = 196.02,
I2 = 86.7%, p < 0.001), and SDOR (Chi-square = 198.32, I2 = 86.9%,
p < 0.001).
The source of heterogeneity was explored by univariate meta-
regression analysis; the results are shown in Table 3. Four variables
were discovered to be explanatory after single factor regression
analysis. We then performed a subgroup analysis to explore
whether the eight factors including the means of infection,
whether or not the samples were collected immediately before
antibiotic therapy, the quality of the studies, region, study
population, the diagnostic infective diseases of the participants,
analytical method, and detecting instrument had an effect on thediagnostic accuracy. The results of the subgroup analysis for CD64
expression on polymorphonuclear neutrophils are presented in
Table 3.
3.5. Publication bias
We used the Egger test to detect publication bias. As shown in
Figure 7, this was statistically signiﬁcant for the studies of CD64 in
the diagnosis of bacterial infection (p < 0.001), showing a
remarkable trend of publication bias.
4. Discussion
The early diagnosis and treatment of bacterial infections
remains a major challenge to clinicians, as the clinical character-
istics of infections resulting from different causative agents are
sometimes similar to each other and they are difﬁcult to tell
apart.54 A missed diagnosis of bacterial infection may result in a
substantial delay in treatment, which may contribute to the high
mortality of that infection. However, the use of antibiotics in those
patients without infection is not only ineffective, but may also lead
to the development of resistance and add the risks of toxicity and
allergic reactions, as well as increases in medical care costs.54 Thus,
a diagnostic biomarker with high sensitivity and speciﬁcity for
bacterial infections is required. The quantiﬁcation of CD64
expression on the surface of neutrophils by ﬂow cytometry has
recently been proposed as a good diagnostic test for bacterial
infection. Neutrophil CD64 expression rapidly increases in a short
time in the presence of stimulating factors like microbial wall
components, IFN-g, and G-CSF.2,12,13 If the stimulations are
AB
C
Diagno stic Odd s Ratio
0.00 1 1000 .01
Mokuda .201 2 161.00     (13 .34  - 1,943 .24 )
Gros.201 2 13 .63       (7.35  - 25 .27)
Hussein .201 0 136 .00      (11.21  - 1,649 .63 )
Tana ka.200 9 72 .33      (1 5.81  - 330 .97 )
Tillinge r.200 9 777.00     (67 .12  - 8,994 .16 )
Cardel li.200 8 475.00     (76 .27  - 2,958 .31 )
Ng.20 06 30 .00      (1 5.34  - 58 .69 )
Livadi ti.200 6 298 .20     (13 .25  - 6,709 .12 )
Ng.20 04 30.03      (1 6.27  - 55 .41 )
Ng.20 02 109 .29     (21 .31  - 560 .52 )
Allen.200 2 57.50      (1 3.12  - 252 .03 )
Diagno stic OR  (95%  CI)
Rand om Effects Mode l
Pooled  Diagno stic  Odds  Ratio  = 65.62  (33 .01  to 130.42 )
Cochran -Q = 30.97;  df  = 10  (p = 0.0006 )
Incon sisten cy (I-squ are)  = 67 .7 %
Tau -squared  = 0.702 8
Specificity
0 0.2 0.4 0.6 0.8 1
Mokuda .201 2
0.92      (0.74  - 0.99 )Gros.201 2
0.89     (0.83 - 0.94 )Hussein.201 0
0.89      (0.65  - 0.99 )Tana ka.200 9
0.98      (0.93  - 1.00 )Tillinge r.200 9
0.97      (0.91  - 1.00 )Carde lli.200 8 0.95      (0.86  - 0.99 )Ng.200 6 0.90     (0.85 - 0.94 )Livadi ti.200 6 1.00      (0.69  - 1.00 )
Ng.200 4 0.89      (0.84  - 0.93 )
Ng.200 2 0.88 (0.77 - 0.95 )
Allen .200 2 0.91     (0.78 - 0.97 )
Spec ificity (95 % CI)
Pooled  Spe cific ity = 0.91  (0.89  to 0.93 )
Chi- square  = 19.08;  df  = 10  (p  = 0.0393 )
Incon sis ten cy (I-squar e) = 47 .6 %
Sensitivity
0 0.2 0.4 0.6 0.8 1
Mokud a.201 2 0.93      (0.68  - 1.00 )
Gros.20 12 0.63      (0.55  - 0.71 )
Huss ein.201 0 0.94      (0.73  - 1.00 )
Tana ka.200 9 0.61      (0.45  - 0.75 )
Til linge r.200 9 0.95      (0.77  - 1.00 )
Cardelli .200 8 0.96      (0.87  - 1.00 )
Ng.200 6 0.77      (0.68  - 0.85 )
Livaditi.200 6 0.95      (0.82  - 0.99 )
Ng.200 4 0.79      (0.71  - 0.86 )
Ng.200 2 0.94      (0.79  - 0.99 )
Allen .200 2 0.85      (0.66  - 0.96 )
Sensitivity (95 % CI)
Pooled  Sensi tivity  = 0.78  (0.75  to  0.82 )
Incon sisten cy (I-squa re)  = 84 .6 %
Chi-square  = 64 .81;  df  = 10  (p = 0.000 )
Figure 5. Forest plots of sensitivity (A) and speciﬁcity (B) and summary diagnostic odds ratio (C) of the 11 studies with proven bacterial infection. The solid circles represent
each individual study, and the diamond represents pooled diagnostic odds ratio. The size of each circle is proportional to the size of the included study. Error bars are 95%
conﬁdence intervals.
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will decrease substantially within 48 h and be back to normal
baseline levels after 7 days.12 Hence neutrophil CD64 expression
can be an indicator of the prognosis for antibiotic therapy in
patients with bacterial infections.41 Additionally, neutrophil CD64
expression is stable in blood samples at room temperature for
more than 30 h, and for more than 72 h at 4 8C.28 Its use would
meet the need in the clinical setting of keeping blood samples
stored, since FCM analysis may not be available on a 24-h basis.
Moreover, CD64 analysis can be done in a few hours with a
minimal blood volume and the test is easy to perform.
We performed this present meta-analysis in compliance with
the recommendations for a reported meta-analysis of diagnostic
tests.30 In our meta-analysis, summary estimates and the SROCwere obtained for the diagnostic accuracy of CD64 expression on
neutrophils in the detection of patients with infection. Accord-
ing to our ﬁndings, CD64 appears to have a good diagnostic
accuracy for bacterial infection since the area under the SROC
curve was 0.92 and the Q* value was 0.85. Furthermore, the
SDOR combines the strengths of sensitivity and speciﬁcity with
the advantage of accuracy as a single indicator. The value of the
SDOR ranges from 0 to inﬁnity, with higher values indicating
greater diagnostic accuracy.55 In the present meta-analysis, the
SDOR was 34.29, and the summary estimates were 0.76 for
sensitivity, 0.85 for speciﬁcity, 6.67 for PLR, and 0.24 for NLR.
Taken together, this indicates that neutrophil CD64 expression
could be considered a useful additional tool for the early
diagnosis of bacterial infection.
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Figure 6. Summary receiver operating characteristic curve of all included studies
(A) and the 11 studies with proven bacterial infection (B) in the diagnosis of
bacterial infection. The solid circles represent each individual study in the meta-
analysis. The size of the circle is proportional to the size of the included study.
S. Li et al. / International Journal of Infectious Diseases 17 (2013) e12–e23e20A previous meta-analysis of the diagnostic performance of
neutrophil CD64 as a biomarker of bacterial infection reported
superior performance of the test compared to our report – the
sensitivity was 0.79 vs. 0.76, and the speciﬁcity was 0.91 vs. 0.85.
However it included only 13 studies with 1921 patients, while we
assessed a total of 26 studies with 3944 patients. Moreover, the
small number of studies might result in a lack of power in detecting
these effects, as they tend to overestimate the effect size.34 In our
meta-analysis, to investigate the source of the heterogeneity, a
threshold analysis, a meta-regression, and a subgroup analysis
were undertaken, as well as an assessment of publication bias.An important purpose of a meta-analysis is to explore the
sources of heterogeneity rather than the computation of a single
summary measure.56 Notably, the differential cut-off values within
the studies could cause a threshold effect.57 Therefore, we ﬁrst
performed a threshold analysis to explore the threshold effect.
However, we found that there was no statistically signiﬁcant
difference. Subsequently potential sources of heterogeneity among
the included studies that appeared to have an effect on the
diagnostic precision were assessed in the meta-regression.
Eventually we discovered that antibiotic therapy (p = 0.09),
QUADAS (p = 0.576), and region (p = 0.704) had no impact on
the diagnostic accuracy, and means of infection (p = 0.031), study
population (p = 0.047), type of infective disease (p = 0.039),
analytical method (p = 0.013), and detecting instrument
(p = 0.010) contributed most of the heterogeneity between
individual studies in the univariate analysis.
In the subgroup analysis, we found some differences between
subgroups. As there has previously been no accepted reference
standard for sepsis and bacterial infection, most of the included
studies used a positive microbiological culture to identify proven
infection cases, and combined this with clinical manifestations
when the microbiological culture was negative to diagnose a
bacterial infection. The sensitivity, speciﬁcity, PLR, NLR, SDOR, and
AUC in the proven infection group were 0.78, 0.91, 8.79, 0.17,
65.62, and 0.96, respectively. Compared to the clinical infection
group, the diagnostic accuracy was higher in the proven infection
group. Some included patients were treated with antibiotics before
blood sample collection because of clinical requirements. We
evaluated the two study groups – studies including those with
samples collected before antibiotic therapy and those with
samples collected after antibiotic therapy. We found the pooled
sensitivity of the CD64 expression test to be only 0.63 in those
patients who had been treated with antibiotics. QUADAS scores
were utilized to assess study quality. We did not ﬁnd the higher
quality studies (QUADAS 11) to have a higher diagnostic
performance than those of lower quality (QUADAS <11). As seen
in Table 3, the region of the study population did not affect the
diagnostic accuracy of the neutrophil CD64 test. We classiﬁed the
study population into two groups according to age. Both the adult
group and the infants/neonates group had almost the same
sensitivity and speciﬁcity, however the SDOR and AUC were
different. The neutrophil CD64 had a better test performance in
adults than in infants and neonates (SDOR: 60.77 vs. 18.34; AUC:
0.94 vs. 0.88). Classifying the studies based on the analytical
method or on the detecting instrument, all the summary estimates
showed great differences between subgroups, especially for SDOR
and AUC. However, signiﬁcant heterogeneity for sensitivity,
speciﬁcity, PLR, NLR, and SDOR was still found between the
included studies. When the studies were sorted according to the
infectious disease the patients suffered, we found a remarkable
difference for rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE) patients compared with infection among
other patients. The corresponding sensitivity, speciﬁcity, PLR, NLR,
and SDOR were 0.89, 0.95, 14.90, 0.13, and 125.59, respectively,
and statistical heterogeneity was not found. Moreover, the AUC for
the detection of bacterial infection in the RA/SLE patients was 0.97
with a Q* value 0.92. So it is believed that neutrophil CD64 is an
excellent biomarker that could distinguish infection in those
patients with RA or SLE. However, a drawback was that the
subgroup only included ﬁve studies with 465 individual cases.
Our meta-analysis was inﬂuenced by publication bias as
shown by the Egger test (Figure 7). Although we performed a
comprehensive systematic electronic search in the databases,
we did not search for unpublished data and eliminated
conference abstracts and letters to journal editors, which may
have led to publication bias. In addition, it is probable that small
Table 3
Results of subgroup analysis for the diagnostic accuracy of CD64 expression on polymorphonuclear neutrophils and univariate regression for the potential variables between studies
Subgroup Studiesa Sensitivity (95%) Speciﬁcity (95%) PLR (95%) NLR (95%) SDOR (95%) AUC Q* Univariate
analysis, p-value
All 27 0.76 (0.74–0.78) 0.85 (0.83–0.86) 6.67 (4.67–9.53) 0.24 (0.18–0.31) 34.29 (19.59–60.01) 0.92 0.85
Infection 0.031
Proven infection 11 0.78 (0.75–0.82) 0.91 (0.89–0.93) 8.79 (6.60–11.69) 0.17 (0.11–0.27) 65.62 (33.01–130.42) 0.96 0.91
Clinical infection 16 0.74 (0.72–0.77) 0.79 (0.77–0.82) 4.67 (3.13–6.98) 0.28 (0.21–0.39) 20.27 (10.25–40.09) 0.88 0.81
Samples collected
before antibiotic therapy
0.09
Yes 14 0.85 (0.82–0.88) 0.88 (0.86–0.90) 7.39 (4.439–12.32) 0.17 (0.12–0.25) 52.51 (24.55–112.32) 0.94 0.88
No 5 0.63 (0.57–0.68) 0.92 (0.89–0.95) 7.77 (4.53–13.34) 0.38 (0.23–0.63) 26.68 (11.18–63.64) 0.92 0.86
Unclear 8 0.72 (0.69–0.75) 0.78 (0.75–0.81) 4.64 (2.66–8.08) 0.30 (0.21–0.43) 18.99 (7.50–48.08) 0.86 0.79
Quality of the studies 0.576
QUADAS 11 17 0.78 (0.75–0.80) 0.86 (0.84–0.88) 7.36 (4.63–11.7) 0.25 (0.19–0.32) 35.70 (19.04–66.95) 0.92 0.85
QUADAS <11 10 0.72 (0.69–0.75) 0.82 (0.79–0.85) 5.88 (3.01–11.46) 0.23 (0.13–0.41) 31.20 (9.47–91.88) 0.91 0.85
Region 0.704
Asia 13 0.80 (0.77–0.83) 0.89 (0.88–0.91) 7.73 (5.09–11.29) 0.23 (0.19–0.30) 40.86 (23.60–70.72) 0.92 0.86
Europe 7 0.78 (0.73–0.82) 0.88 (0.83–0.91) 5.89 (2.41–14.39) 0.25 (0.16–0.41) 26.17 (8.96–76.42) 0.91 0.84
North America 5 0.74 (0.68–0.79) 0.79 (0.74–0.83) 7.14 (1.99–25.56) 0.22 (0.08–0.61) 37.87 (4.75–602.08) 0.94 0.88
Other 2 0.67 (0.62–0.72) 0.67 (0.60–0.73) 3.45 (0.78–15.23) 0.22 (0.01–0.42) 17.62 (0.49–628.49) 0.5 0.5
Study population 0.047
Adults 16 0.76 (0.73–0.78) 0.87 (0.85–0.89) 9.25 (5.02–17.04) 0.19 (0.13–0.28) 60.77 (23.56–156.79) 0.94 0.88
Infants/neonates 11 0.75 (0.72–0.78) 0.82 (0.79–0.84) 4.81 (3.09–7.47) 0.29 (0.20–0.44) 18.34 (9.56–35.19) 0.88 0.81
Type of infective disease 0.039
Sepsis 15 0.73 (0.70–0.75) 0.81 (0.79–0.83) 5.21 (3.45–7.87) 0.28 (0.20–0.38) 22.09 (11.36–42.95) 0.91 0.84
RA/SLE with infection 5 0.89 (0.82–0.93) 0.95 (0.92–0.97) 14.90 (9.21–24.123) 0.13 (0.07–0.25) 125.59 (54.48–289.51) 0.97 0.92
Other infection 7 0.81 (0.77–0.85) 0.89 (0.86–0.92) 7.66 (3.04–19.30) 0.26 (0.17–0.40) 38.55 (12.22–121.60) 0.92 0.85
Analytical method 0.013
FCM 18 0.80 (0.77–0.83) 0.90 (0.89–0.92) 9.07 (6.25–13.12) 0.19 (0.13–0.28) 54.59 (30.73–96.99) 0.95 0.89
Leuko64 kit 9 0.71 (0.68–0.74) 0.74 (0.70–0.77) 3.44 (2.25–5.27) 0.35 (0.27–0.46) 12.37 (5.90–25.95) 0.85 0.78
Detecting instrument 0.01
BD FACSCalibur 21 0.82 (0.79–0.84) 0.87 (0.86–0.89) 8.22 (5.28–12.81) 0.20 (0.16–0.27) 50.43 (26.43–96.21) 0.93 0.87
Coulter Epic XL-MCL 5 0.66 (0.62–0.69) 0.76 (0.72–0.80) 3.33 (1.88–5.91) 0.44 (0.31–0.63) 8.60 (3.83–19.28) 0.81 0.74
AUC, area under the curve; FCM, ﬂow cytometry; NLR, negative likelihood ratio; PLR, positive likelihood ratio; QUADAS, quality assessment for studies of diagnostic accuracy; RA, rheumatoid arthritis; SDOR, summary diagnostic
odds ratio; SLE, systemic lupus erythematosus.
a The number of studies included in the meta-analysis.
S.
 Li
 et
 a
l.
 /
 In
tern
a
tio
n
a
l
 Jo
u
rn
a
l
 o
f
 In
fectio
u
s
 D
isea
ses
 1
7
 (2
0
1
3
)
 e1
2
–
e2
3
 
e2
1
Egger's publication bias plot
S
ta
nd
ar
di
ze
d 
ef
fe
ct
Precision
0 2 4 6
0
5
10
p < 0.001 
Figure 7. Egger test for the assessment of potential publication bias in neutrophil
CD64 expression in the diagnosis of bacterial infection.
S. Li et al. / International Journal of Infectious Diseases 17 (2013) e12–e23e22studies with small sample sizes tended to report overestima-
tions of diagnostic performance.34 Another interpretation for the
publication bias is that there is a greater tendency to publish
studies with positive results, and those with negative results are
less likely to be published.
Some limitations of the present meta-analysis should be
considered. First, the original studies lacked information on key
elements of the study design and the baseline characteristics of the
patients, and this precluded an analysis of the effect of these
factors. Second, in terms of infection, CD64 expression has been
reported to be induced not only by bacteria, but also by
viruses.37,54 Also, the patients suffering from bacterial infections
sometimes have clinical characteristics similar to those with viral
infections, and it is hard to distinguish by traditional tests and the
clinical manifestations. So in our included studies, some patients
with viral infections might have been treated as bacterial
infections. Third, some patients who had already received
antibiotics at the time of study entry were included in the studies
because of the requirement for critically ill patients.45 This would
result in a lower sensitivity.27 Fourth, some of the included studies
contained small numbers of cases and the backgrounds of patients
varied. Finally, substantial heterogeneity for the pooled estimates
was recorded, except for RA/SLE patients, which may be attributed
to the difference in the means of diagnosis of the bacterial
infection, the age of the study populations, analytical methods,
detecting instruments, and the varied status of the patients across
included trials. Furthermore, cost-effectiveness was not evaluated
in our meta-analysis, which therefore needs to be done in future
studies.
In conclusion, the results of this meta-analysis demonstrate
that CD64 expression on neutrophils is a reliable biomarker for the
early diagnosis of bacterial infection since it has a good overall
diagnostic performance. However, due to the fact that cut-off
values vary greatly for CD64 expression on neutrophils, before it
can be used widely in the clinical setting, more large prospective
studies must be carried out according to standardized protocols in
order to appropriately evaluate its accuracy. Regarding the higher
diagnostic accuracy of neutrophil CD64 for RA and SLE patients
with bacterial infection, more evidence is needed to conﬁrm this.Funding: The work described in this paper was not supported by
any kind of funding.
Conﬂict of interest: All the authors declare that they have no
conﬂicts of interest.
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